Yusuke Naoi
Research Subjects
Yusuke Naoi has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Daisuke Ennishi
Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan
26 shared publications - Caiyang Fang
Okayama University 1 Okayama
24 shared publications - Hirofumi Hamano
Department of Pharmacy, Okayama University Hospital, Okayama, Japan
24 shared publications - Isamu Okamoto
Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
24 shared publications - Joji Nagasaki
Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan
24 shared publications - Kadoaki Ohashi
Department of Respiratory Medicine Okayama University Hospital Okayama Japan
24 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Elsevier in Osteoarthritis and Cartilage
Spatial architecture of the synovium identifies clinically relevant phenotypes of osteoarthritis
- 4 November 2026
- Published by Elsevier in Osteoarthritis and Cartilage
Open AccessSpatial architecture of the synovium identifies clinically relevant phenotypes of osteoarthritis
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Gating strategy for T follicular helper (TFH) cells in flow cytometry analysis
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Gating strategy for T follicular helper (TFH) cells in flow cytometry analysis
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Multicolor immunohistochemistry images for CD4, CD8, and FOXP3 in FL and DLBCL
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Multicolor immunohistochemistry images for CD4, CD8, and FOXP3 in FL and DLBCL
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Definition of radiotherapy in this study
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Definition of radiotherapy in this study
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Immunohistochemistry for CD40, IL-4R, and IL-21R of cases 1 and 2
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Immunohistochemistry for CD40, IL-4R, and IL-21R of cases 1 and 2
- Open Access
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Patient selection flowchart in the VigiBase database
- 17 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy
Patient selection flowchart in the VigiBase database